Future studies should include longitudinal tracking from clonal hematopoiesis through ET onset, HSC-specific conditional CXCR4 deletion combined with fate-mapping, single-cell multi-omics for TN-ET, and mutation-stratified clinical trials incorporating serial HSC profiling. The gene discussed is CXCR4; the disease is essential thrombocythemia.